Exercise in advanced prostate cancer elevates myokine levels and suppresses in-vitro cell growth.

Kim, J-S; Taaffe, DR; Galvão, DA; Hart, NH; Gray, E; Ryan, CJ; Kenfield, SA; Saad, F; Newton, RU

Exercise in advanced prostate cancer elevates myokine levels and suppresses in-vitro cell growth.

Kim, J-S Taaffe, DR Galvão, DA Hart, NH Gray, E Ryan, CJ Kenfield, SA Saad, F Newton, RU

Permalink

Publisher:: Springer Nature [academic journals on nature.com]
Publication Type:: Journal Article
Citation:: Prostate Cancer and Prostatic Diseases, 2022, 25, (1), pp. 86-92
Issue Date:: 2022-03

Open Access

Copyright Clearance Process

Recently Added
In Progress
Open Access

This item is open access.

Download full textAdobe PDF (688.87 kB)

View on publisher's site

View statistics

Full metadata record

Field	Value	Language
dc.contributor.author	Kim, J-S
dc.contributor.author	Taaffe, DR
dc.contributor.author	Galvão, DA
dc.contributor.author	Hart, NH
dc.contributor.author	Gray, E
dc.contributor.author	Ryan, CJ
dc.contributor.author	Kenfield, SA
dc.contributor.author	Saad, F
dc.contributor.author	Newton, RU
dc.date.accessioned	2022-10-28T03:17:19Z
dc.date.available	2022-01-20
dc.date.available	2022-10-28T03:17:19Z
dc.date.issued	2022-03
dc.identifier.citation	Prostate Cancer and Prostatic Diseases, 2022, 25, (1), pp. 86-92
dc.identifier.issn	1365-7852
dc.identifier.issn	1476-5608
dc.identifier.uri	http://hdl.handle.net/10453/162806
dc.description.abstract	BACKGROUND: Altering the systemic milieu through exercise has been proposed as a potential mechanism underlying exercise-driven tumour suppression. It is not yet known whether men with advanced prostate cancer can elicit such adaptations following a program of exercise. The purpose is to examine myokine levels of serum acquired from metastatic castrate-resistant prostate cancer (mCRPC) patients recruited to the INTERVAL-GAP4 trial before and after 6 months of exercise and its tumour-suppressive effect. METHODS: Twenty-five men with mCRPC (age = 74.7 ± 7.1 yrs) were randomised to supervised multimodal (aerobic and resistance) exercise (EX) or self-directed exercise control group (CON). Body composition was assessed using dual-energy x-ray absorptiometry (DXA), and fasting blood in a rested state was collected at baseline and at 6 months. Serum levels of myokines (SPARC, OSM, decorin, IGF-1, and IGFBP-3) were measured. Serum was applied to the prostate cancer cell line DU145, and growth was assessed for 72 h. RESULTS: No significant change in body composition was observed. Adjusted serum OSM (P = 0.050) and relative OSM (P = 0.083), serum SPARC (P = 0.022) and relative SPARC (P = 0.025) increased in EX compared to CON. The area under curve (AUC) over 72 h showed a significant reduction in DU145 growth after applying post-intervention serum from the EX vs CON (P = 0.029). CONCLUSION: Elevated myokine expressions and greater tumour-suppressive effects of serum after 6 months of periodised and autoregulated supervised exercise was observed in men with mCRPC. Exercise-induced systemic changes may slow disease progression in men with advanced prostate cancer.
dc.format	Print-Electronic
dc.language	eng
dc.publisher	Springer Nature [academic journals on nature.com]
dc.relation	http://purl.org/au-research/grants/nhmrc/1116334
dc.relation.ispartof	Prostate Cancer and Prostatic Diseases
dc.relation.isbasedon	10.1038/s41391-022-00504-x
dc.rights	info:eu-repo/semantics/openAccess
dc.subject	1112 Oncology and Carcinogenesis
dc.subject.classification	Urology & Nephrology
dc.subject.mesh	Aged
dc.subject.mesh	Aged, 80 and over
dc.subject.mesh	Body Composition
dc.subject.mesh	Cell Proliferation
dc.subject.mesh	Exercise
dc.subject.mesh	Exercise Therapy
dc.subject.mesh	Humans
dc.subject.mesh	Male
dc.subject.mesh	Prostatic Neoplasms
dc.subject.mesh	Prostatic Neoplasms, Castration-Resistant
dc.subject.mesh	Aged
dc.subject.mesh	Aged, 80 and over
dc.subject.mesh	Body Composition
dc.subject.mesh	Cell Proliferation
dc.subject.mesh	Exercise
dc.subject.mesh	Exercise Therapy
dc.subject.mesh	Humans
dc.subject.mesh	Male
dc.subject.mesh	Prostatic Neoplasms
dc.subject.mesh	Prostatic Neoplasms, Castration-Resistant
dc.subject.mesh	Humans
dc.subject.mesh	Prostatic Neoplasms
dc.subject.mesh	Exercise
dc.subject.mesh	Exercise Therapy
dc.subject.mesh	Cell Proliferation
dc.subject.mesh	Body Composition
dc.subject.mesh	Aged
dc.subject.mesh	Aged, 80 and over
dc.subject.mesh	Male
dc.subject.mesh	Prostatic Neoplasms, Castration-Resistant
dc.title	Exercise in advanced prostate cancer elevates myokine levels and suppresses in-vitro cell growth.
dc.type	Journal Article
utslib.citation.volume	25
utslib.location.activity	England
utslib.for	1112 Oncology and Carcinogenesis
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Health
utslib.copyright.status	open_access	*
pubs.consider-herdc	false
dc.date.updated	2022-10-28T03:17:16Z
pubs.issue	1
pubs.publication-status	Published
pubs.volume	25
utslib.citation.issue	1

Abstract:

BACKGROUND: Altering the systemic milieu through exercise has been proposed as a potential mechanism underlying exercise-driven tumour suppression. It is not yet known whether men with advanced prostate cancer can elicit such adaptations following a program of exercise. The purpose is to examine myokine levels of serum acquired from metastatic castrate-resistant prostate cancer (mCRPC) patients recruited to the INTERVAL-GAP4 trial before and after 6 months of exercise and its tumour-suppressive effect. METHODS: Twenty-five men with mCRPC (age = 74.7 ± 7.1 yrs) were randomised to supervised multimodal (aerobic and resistance) exercise (EX) or self-directed exercise control group (CON). Body composition was assessed using dual-energy x-ray absorptiometry (DXA), and fasting blood in a rested state was collected at baseline and at 6 months. Serum levels of myokines (SPARC, OSM, decorin, IGF-1, and IGFBP-3) were measured. Serum was applied to the prostate cancer cell line DU145, and growth was assessed for 72 h. RESULTS: No significant change in body composition was observed. Adjusted serum OSM (P = 0.050) and relative OSM (P = 0.083), serum SPARC (P = 0.022) and relative SPARC (P = 0.025) increased in EX compared to CON. The area under curve (AUC) over 72 h showed a significant reduction in DU145 growth after applying post-intervention serum from the EX vs CON (P = 0.029). CONCLUSION: Elevated myokine expressions and greater tumour-suppressive effects of serum after 6 months of periodised and autoregulated supervised exercise was observed in men with mCRPC. Exercise-induced systemic changes may slow disease progression in men with advanced prostate cancer.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/162806